The pharmaceutical landscape is currently dominated by a “gold rush” in metabolic health. As of early 2026, the global success of existing treatments has paved the way for a second generation of Glucagon-Like Peptide-1 (GLP-1) receptor agonists currently in Phase-3 trials. For manufacturers and quality control labs, this surge brings a complex set of analytical challenges: navigating the rigorous impurity standards required for these increasingly sophisticated (bio)synthetic molecules.
The Phase-3 Pipeline: Beyond Simple GLP-1 Agonism
Current Phase-3 candidates are moving toward “poly-agonism”—targeting multiple receptors simultaneously to maximize weight loss and glycemic control.
- Retatrutide: A triple agonist targeting GIP, GLP-1, and glucagon receptors, built on a GIP peptide backbone with a C20 fatty diacid conjugation for extended half-life. Phase-3 TRIUMPH trials are well advanced, with TRIUMPH-4 topline results already reported in late 2025 and seven additional readouts expected through 2026. Its 39-amino acid sequence requires hyper-specific standards to monitor for truncated sequences and D-amino acid isomers.
- Orforglipron: A significant shift as a non-peptide, small-molecule oral GLP-1. Unlike traditional peptides, its impurity profile will follow standard ICH Q3A/B guidelines, focusing on process catalysts and degradation rather than peptide-related substances.
- CagriSema: A fixed-dose combination of semaglutide and the amylin analogue cagrilintide. Analyzing impurities in a co-formulated product requires advanced orthogonal methods, such as 2D-LC or HILIC-MS, to distinguish between degradation products of two different peptides in a single vial.
- Survodutide: A dual GLP-1 and glucagon receptor agonist undergoing Phase-3 SYNCHRONIZE trials for obesity management in adults with and without type 2 diabetes. A separate Phase-3 program, LIVERAGE, evaluates survodutide for MASH and hepatic fibrosis. Both programs demand high-purity standards capable of withstanding rigorous stability testing across distinct patient populations.
The Impurity Mandate: Why 0.1% Matters
For any laboratory supporting GLP-1 development, the regulatory bar is exceptionally high. Because many GLP-1s are synthetic or hybrid-recombinant peptides, they sit in a unique regulatory space.
- The Sameness Criteria: For generic GLP-1s to be approved via the ANDA pathway, the impurity profile must be “the same as or better than” the Reference Listed Drug (RLD).
- New Impurity Thresholds: FDA guidance for synthetic peptides dictates that any new impurity (not found in the RLD) between 0.10% and 0.5% must undergo rigorous in vitro immunogenicity risk assessment.
- The 0.5% Hard Cap: New peptide-related impurities exceeding 0.5% are generally not acceptable for generic approval without extensive clinical data.
Technical Corner: MS Identification of GLP-1 Impurities
The challenge in GLP-1 impurity analysis is not simply detecting what is there — it is knowing which tool to reach for first, and when the first tool is no longer enough. No single analytical platform covers the full impurity landscape of a synthetic or semi-synthetic peptide. UHPLC-HRMS serves as the primary engine, but it has a hard boundary: it is blind to stereochemistry. Understanding where that boundary sits — and what sits beyond it — is what separates a reactive QC function from one that anticipates regulatory scrutiny.
1. UHPLC-HRMS: The Primary Engine
UHPLC coupled to high-resolution mass spectrometry (Orbitrap or Q-TOF platforms) offers sub-5 ppm mass accuracy, which translates directly into the ability to assign molecular formulas to trace-level degradants without a reference standard in hand. For long-chain peptides like retatrutide (39 amino acids) or the dual-component CagriSema, this matters because the degradant space is wide: oxidation, deamidation, truncation, and acetylation can each produce multiple co-existing species at levels approaching the 0.10% immunogenicity threshold.
The HRMS software workflow generates b- and y-ion series from MS/MS fragmentation, enabling unambiguous localisation of modifications — for instance, confirming whether an oxidation event sits on Met or on the Trp residue of a specific sequence position. For impurities with no database match, de novo sequencing tools reconstruct the peptide sequence purely from fragment ion patterns, removing dependence on a pre-built spectral library. This is particularly valuable during early Phase-3 stability studies, when the degradant map is still being drawn.
2. Where CID Fragmentation Reaches Its Limit: Isomeric Residues
Standard collision-induced dissociation (CID) cannot distinguish between residue pairs that share identical nominal masses: Leucine/Isoleucine (Leu/Ile) and Tryptophan/Iso-Tryptophan (Trp/Iso-Trp) both produce overlapping fragment ion series under CID conditions. For molecules whose potency or immunogenicity profile is sensitive to the precise residue at a given position, this ambiguity is analytically unacceptable.
Advanced electron-based dissociation modes resolve this. Electron Capture Dissociation (ECD) and Electron Transfer Dissociation (ETD) generate c- and z-type fragment ions that preserve labile side-chain bonds, producing characteristic fragmentation patterns that differentiate Leu from Ile at specific sequence positions. ETD is also the method of choice for disulfide bond characterisation — increasingly relevant as next-generation GLP-1 conjugates incorporate cysteine-bridged fatty acid linkers designed for albumin binding and half-life extension.
The hard limit, however, is D-amino acid epimers. Racemisation at chiral centres — a documented risk during extended solid-phase peptide synthesis (SPPS) cycles or under accelerated stability conditions — produces diastereomers with an exact mass difference of 0.000 Da.
3. 2D-LC-HRMS: Resolving Co-eluting Impurities in Complex Matrices
Co-formulated products like CagriSema present an additional complication: degradation products from two structurally distinct peptides — semaglutide and cagrilintide — can co-elute under standard reversed-phase conditions. Single-dimension LC, even with HRMS detection, cannot assign a peak unambiguously when two species share a retention window.
Two-dimensional LC resolves this through orthogonal separation chemistry. RP-RP 2D-LC exploits pH differences between dimensions to resolve peptides with similar hydrophobicity under matching stationary phase chemistry. RP-HILIC 2D-LC takes a more contrasting approach: the hydrophilic interaction dimension retains highly polar degradants and glycosylated species that reverse-phase would elute near the solvent front, providing clean separation of the most problematic co-eluters. Both modes are routinely coupled to HRMS for real-time identification of re-separated fractions, making the full workflow genuinely quantitative rather than merely qualitative
4. Common m/z Shifts: A Reference Guide for GLP-1 Analogue Characterisation
The table below captures the most frequently encountered mass shifts during GLP-1 analogue synthesis and stability testing. Each entry includes the analytical challenge specific to GLP-1 molecules — because the difficulty is rarely in knowing the shift exists, but in resolving it from the noise of a structurally complex peptide matrix.
| Impurity Type | Chemical Cause | Mass Shift (Da) | Analytical Challenge |
| Deamidation | Asn/Gln → Asp/Glu conversion | +0.984 | Tiny shift; demands >100,000 resolving power. Common at Asn8 in semaglutide. |
| Oxidation | O addition to Trp or Met residues | +15.995 | Generates multiple sulfoxide peaks; site localisation requires MS/MS. |
| Acetylation | N-terminal capping or Lys side-chain (SPPS artefact) | +42.011 | Common process impurity in SPPS; overlaps trimethylation (+42.047) without HRMS. |
| Sodium Adduct | Interaction with glassware or Na-containing reagents | +22.990 | Suppresses [M+H]+ signal; complicates quantitation without charge-state deconvolution. |
| Truncation | Loss of N- or C-terminal amino acids during SPPS | Variable (large) | Critical for potency; de novo sequencing needed for long truncations in 39-aa peptides like retatrutide. |
| Diastereomers (D-amino acids) | Racemisation at chiral centres during SPPS or storage | 0.000 (invisible to MS) | MS-invisible. Requires chiral chromatography (e.g., Daicel CHIRALPAK® columns) for detection and quantitation. |
| His-Cyclic (Hydantoin) | N-terminal His cyclisation to hydantoin derivative (degradation) | −18.011 | Significantly reduces biological activity. Relevant to all His1-containing GLP-1 analogues incl. semaglutide and liraglutide. |
Note on the His-Cyclic Variant: The hydantoin derivative arises specifically in GLP-1 analogues with a free N-terminal histidine (His1) — which includes semaglutide and liraglutide. The −18.011 Da loss is detectable by HRMS but requires a certified impurity standard for confident quantitation, since the shift overlaps with other dehydration artefacts in a complex degradant mixture. Daicel supplies certified standards for the major GLP-1 analogue impurities, including His-cyclic variants, to support both method development and regulatory filing.
Conclusion: Quality as the Competitive Edge
As the market for GLP-1s expands into Alzheimer’s disease, cardiovascular health, and MASH — each new indication adds its own analytical layer. CNS-targeted formulations will require blood-brain barrier penetration profiling, while cardiac endpoints demand longer stability windows. In every case, the speed-to-market for new therapies and generics will depend on analytical precision. Utilizing high-quality impurity standards for the upcoming generation of agonists is no longer just a compliance step, it is a strategic necessity to ensure patient safety and regulatory success.
Reflecting its rich experience in the field, Daicel Chiral Technologies India supports GLP-1 peptide development programs by providing comprehensive analytical services along with certified impurity standards, enabling robust characterization, method development, and regulatory-ready quality control throughout the drug development lifecycle. Partner with Daicel to accelerate your GLP-1 programs.
Disclaimer: All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. The chemical names and structures discussed are provided for analytical research and development purposes only to support the identification of impurities in accordance with global regulatory standards. Any discussion of Phase-3 candidates is based on publicly available clinical trial data and does not constitute medical or investment advice.
Write a comment
Your email address will not be published. All fields are required